A scientific claim is a generalization based on a reported statistically significant effect. The reproducibility of that claim is its scientific meaning. Anything not explicitly mentioned in a scientific claim as a limitation of the claim's scope means that it implicitly generalizes over these unmentioned aspects. Hence, so-called "conceptual" replications that differ in these unmentioned aspects from the original study are legitimate, and necessary to test the generalization implied by the original study's claim.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S0140525X18000602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elevated PD-1 and PDL-1 autoantibodies and association with tuberculosis.
J Infect
January 2025
Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, Shenzhen University Medical School, Shenzhen 518060, China. Electronic address:
Poor scholarship and unacknowledged bias: Commentary on Walker et al. (2025).
Am Psychol
January 2025
The article by Walker et al. (2025) titled "The American Psychological Association and Antisemitism: Toward Equity, Diversity, and Inclusion" regrettably suffers from serious shortcomings in regard to scholarship. These include flawed analyses, an overreliance on unreliable and biased sources, and the presentation of provocative and significant claims without any documentation at all.
View Article and Find Full Text PDFCardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study.
J Intern Med
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Background: Evolving evidence suggests that patients undergoing treatment with Janus kinase inhibitors (JAKi) may face an increased risk of cardiovascular events, malignancies, and serious infections.
Objectives: We assessed cardiovascular, malignancy, and serious infection risks associated with JAKi use compared to tumor necrosis factor inhibitor (TNFi) use, which served as the active comparator, in patients with rheumatoid arthritis (RA) or ulcerative colitis (UC).
Methods: This study emulated a target trial using South Korea's nationwide claims database (2013-2023).
Healthcare Resource Utilization Among Patients With Generalized Pustular Psoriasis: The Impact of Flares and Disease Severity.
J Psoriasis Psoriatic Arthritis
January 2025
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Background: Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of painful, sterile pustules often accompanied by systemic symptoms. The impact of GPP flares and underlying GPP severity on the healthcare resource utilization (HCRU) is not well characterized.
Objective: To quantify HCRU among US GPP patients by flare status and underlying severity.
Association between the triglyceride/high-density lipoprotein (TG/HDL) ratio and incidence of gout: A nationwide cohort study.
Front Endocrinol (Lausanne)
January 2025
Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Introduction: The global burden of gout, a severe and painful arthralgia, is of note and is expected to increase in the future. We aimed to investigate the association between the triglyceride/high-density lipoprotein (TG/HDL) ratio, a simple and validated biomarker for insulin resistance, and the incidence of gout in a longitudinal setting in the general population.
Methods: Our study was conducted using the National Health Insurance Service-Health Screening Cohort database of Republic of Korea (2002-2019).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!